Kenneth A. Krohn

Kenneth A. Krohn

Auto-generated profile, based on publicly available information

Kenneth A. Krohn

Molecular Imaging Research, Box356004, Department of Radiology, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195-6004, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2004
Verified
Journal Article
Closed access
ASAlexander M Spence
Alexander M Spence
MMMark Muzi
Mark Muzi
DMDavid A Mankoff
David A Mankoff
SOS Finbarr O'Sullivan
S Finbarr O'Sullivan
JLJeanne M Link
Jeanne M Link
KKKenneth A Krohn
Kenneth A Krohn

1 October 2006
Verified
Journal Article
Closed access
MMMark Muzi
Mark Muzi
ASAlexander M Spence
Alexander M Spence
FOFinbarr O'Sullivan
Finbarr O'Sullivan
DMDavid A Mankoff
David A Mankoff
JWJoanne M Wells
Joanne M Wells
KKKenneth A Krohn
Kenneth A Krohn

1 September 2002
Verified
Journal Article
Closed access
MGMichael M Graham
Michael M Graham
MMMark Muzi
Mark Muzi
ASAlexander M Spence
Alexander M Spence
FOFinbarr O'Sullivan
Finbarr O'Sullivan
TLThomas K Lewellen
Thomas K Lewellen
KKKenneth A Krohn
Kenneth A Krohn

1 September 2003
Verified
Journal Article
Closed access
HVHubert Vesselle
Hubert Vesselle
JGJohn Grierson
John Grierson
LPLanell M Peterson
Lanell M Peterson
MMMark Muzi
Mark Muzi
DMDavid A Mankoff
David A Mankoff
KKKenneth A Krohn
Kenneth A Krohn

1 July 2002 in Molecular Imaging
Verified
Journal Article
Open access
JWJoanne M. Wells
Joanne M. Wells
DMDavid A. Mankoff
David A. Mankoff
JEJanet F. Eary
Janet F. Eary
ASAlexander M. Spence
Alexander M. Spence
MMMark Muzi
Mark Muzi
KKKenneth A. Krohn
Kenneth A. Krohn
2-[11C]Thymidine (TdR), a PET tracer for cellular proliferation, may be advantageous for monitoring brain tumor progression and response to therapy. Kinetic analysis of dynamic TdR images was performed to estimate the rate of thymidine transport (K1t) and thymidine flux (KTdR) into brain tumors and normal brain. These estimates were compared to MRI and pathologic results. Twenty patients underwent sequential [11C]CO2 (major TdR metabolite) and TdR PET studies with arterial blood sampling and metabolite analysis. The data were fitted using the five-compartment model described in the companion article. Comparison of model estimates with clinical and pathologic data shows that K1t is higher for MRI contrast enhancing tumors (p < .001), and KTdR increases with tumor grade (p < .02). On average, TdR retention was lower after treatment in high-grade tumors. The model was able to distinguish between increased thymidine transport due to blood-brain barrier breakdown and increased tracer retention associated with tumor cell proliferation. Initial analysis of model estimates of thymidine retention and transport show good agreement with the clinical and pathological features of a wide range of brain tumors. Ongoing studies will evaluate its role in measuring response to treatment and predicting outcome.

4 March 2015
Verified
Journal Article
Closed access
MPM Peck
M Peck
HPH A Pollack
H A Pollack
AFA Friesen
A Friesen
MMM Muzi
M Muzi
SSS C Shoner
S C Shoner
KKK A Krohn
K A Krohn